Kadcyla 100 & 160 Mg 100 & 160 mg Powder for concentrate for solution for infusion
PDF Leaflet Revision Date: 05 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Adjuvant treatment for HER2-positive early breast cancer and monotherapy for HER2-positive metastatic breast cancer.
Dosage (summary)
3.6 mg/kg IV every 3 weeks; initial infusion over 90 mins, subsequent doses over 30 mins if tolerated.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required during treatment.
Key Drug Interactions
- Avoid strong CYP3A4 inhibitors
Contraindications
- Hypersensitivity to trastuzumab emtansine or excipients
- Pregnancy
- Lactation
Common side effects
- Nausea
- Fatigue
- Headache
- Thrombocytopenia
- Peripheral neuropathy
Counselling Points
- Monitor for infusion reactions
- Report any signs of liver dysfunction
- Avoid pregnancy during treatment
Serious warnings
- Risk of left ventricular dysfunction
- Pulmonary toxicity
- Hepatotoxicity
- Infusion-related reactions
Important Disclaimer
The Kadcyla 100 & 160 Mg 100 & 160 mg Powder for concentrate for solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
